These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 27768923

  • 1. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F, ARTBC International.
    Eur J Cancer; 2016 Nov; 68():163-172. PubMed ID: 27768923
    [Abstract] [Full Text] [Related]

  • 2. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M, Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International).
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [Abstract] [Full Text] [Related]

  • 3. Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A.
    Br J Cancer; 2017 Sep 26; 117(7):965-973. PubMed ID: 28817838
    [Abstract] [Full Text] [Related]

  • 4. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J.
    Lancet Oncol; 2014 May 26; 15(6):601-11. PubMed ID: 24717919
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, Leonard G, D'Angelica M, DeMatteo R, Blumgart L, Fong Y.
    J Clin Oncol; 2005 Aug 01; 23(22):4888-96. PubMed ID: 16009951
    [Abstract] [Full Text] [Related]

  • 6. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH.
    PLoS Med; 2024 May 01; 21(5):e1004389. PubMed ID: 38728364
    [Abstract] [Full Text] [Related]

  • 7. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
    Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V.
    Clin Colorectal Cancer; 2017 Sep 01; 16(3):e191-e198. PubMed ID: 27979717
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D, Benhaim L, Bonnet S, Malka D, Faron M, Elias D, Lefèvre JH, Deschamps F, Dromain C, Boige V, Dumont F, De Baere T, Ducreux M.
    Ann Surg; 2013 Jan 01; 257(1):114-20. PubMed ID: 23235397
    [Abstract] [Full Text] [Related]

  • 9. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M.
    Ann Surg Oncol; 2008 Jan 01; 15(1):219-26. PubMed ID: 17896145
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
    Volovat SR, Volovat C, Negru SM, Danciu M, Scripcariu V.
    J Chemother; 2016 Jun 01; 28(3):235-41. PubMed ID: 26018108
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
    Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E.
    Clin Pharmacokinet; 2017 Feb 01; 56(2):165-177. PubMed ID: 27393140
    [Abstract] [Full Text] [Related]

  • 12. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI.
    J Surg Oncol; 2018 Mar 01; 117(4):634-643. PubMed ID: 29165816
    [Abstract] [Full Text] [Related]

  • 13. Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.
    Lim A, Le Sourd S, Senellart H, Luet D, Douane F, Perret C, Bouvier A, Métairie S, Cauchin E, Rougier P, Matysiak-Budnik T, Touchefeu Y.
    Clin Colorectal Cancer; 2017 Dec 01; 16(4):308-315. PubMed ID: 28433600
    [Abstract] [Full Text] [Related]

  • 14. Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure.
    Sato Y, Inaba Y, Ura T, Nishiofuku H, Yamaura H, Kato M, Takahari D, Tanaka T, Muro K.
    J Gastrointest Cancer; 2018 Jun 01; 49(2):132-137. PubMed ID: 28058527
    [Abstract] [Full Text] [Related]

  • 15. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
    Allard MA, Sebagh M, Baillie G, Lemoine A, Dartigues P, Faitot F, Faron M, Boige V, Vitadello F, Vibert E, Elias D, Adam R, Goéré D, Sa Cunha A.
    Ann Surg Oncol; 2015 Jun 01; 22(6):1925-32. PubMed ID: 25448804
    [Abstract] [Full Text] [Related]

  • 16. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.
    Neyns B, Aerts M, Van Nieuwenhove Y, Fontaine C, De Coster L, Schallier D, Vanderauwera J, De Munck F, Vandenbroucke F, Everaert H, Meert V, De Mey J, De Ridder M, Delvaux G, De Grève J.
    Anticancer Res; 2008 Jun 01; 28(4C):2459-67. PubMed ID: 18751435
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N.
    Ann Surg; 2015 Feb 01; 261(2):353-60. PubMed ID: 24646562
    [Abstract] [Full Text] [Related]

  • 18. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M, Chen SC, Ying HY, Zhao L, Li XY, Zhou JF, Shao YJ, Yang XD, Lin Y, Ning XH, Bai CM.
    Chin Med J (Engl); 2012 Oct 01; 125(20):3640-5. PubMed ID: 23075717
    [Abstract] [Full Text] [Related]

  • 19. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
    Chen Y, Wang X, Yan Z, Wang J, Luo J, Liu Q.
    Onkologie; 2012 Oct 01; 35(9):480-4. PubMed ID: 23007144
    [Abstract] [Full Text] [Related]

  • 20. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.
    Ann Oncol; 2014 May 01; 25(5):1018-25. PubMed ID: 24585720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.